Tag: OGXI

OncoGenex Update (9-23-15)

BIOINVEST BREAKING NEWS – Special Update – OncoGenex (OGXI) – Rainier Fails To Show A Benefit in Apatorsen in Metastic Pancreatic Cancer; Not Really A Surprise & Many More Shots To Go – Our BUY Thesis Remains Intact – While we do not have exact details, the addition of apatorsen to ABRAXANE and gemcitabine did not demonstrate a survival benefit compared to ABRAXANE and gemcitabine alone.. read more…

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 809

Issue No. 809 (dated 8/20/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ACAD #ANTH #NVAX #OGXI #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 804

Issue No. 804 (dated 5/29/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #FPRX, #CBMG, #INCY and #OGXI

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

OncoGenex Update (2-13-13)

OGXI has started their fourth Phase II trial testing OGX-427 in cancer patients.  Borealis-2 is being initiated as an investigator-sponsored, randomized, controlled Phase II trial of 427 in patients with advanced or metastatic bladder cancer (http://clinicaltrials.gov/ct2/show/NCT01454089?term=Oncogenex&rank=1). This trial will evaluate the potential of ‘427 to work synergistically with second- or third-line chemotherapy to overcome treatment[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Life Sciences Report (9-16-15)

An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.

Posted on by

MTSL Issue 807

Issue No. 807 (dated 7/23/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #BMRN #ISIS #MDCO #NKTR #NVAX

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

OncoGenex Update (4-28-14)

OncoGenex Update (4-28-14) OGXI – OncoGenex’ Custirsen SYNERGY Trial Falls Short – In a major disappointment, OGXI and their partner TEVA announced top-line SYNERGY results that fell short. 

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

OncoGenex Update (12-21-12)

OncoGenex has announced the start of PACIFIC, an investigator-sponsored, randomized Phase II trial testing OGX-427 in 80 men with metastatic castrate-resistant prostate cancer (CRPC) who are experiencing a rising PSA while receiving JNJ’s Zytiga (abiraterone acetate). The aim of the study is to determine if adding 427 to Zytiga treatment can reverse or delay treatment[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 810

Issue No. 810 (dated 9/03/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ACAD #ANTH #INCY #OGXI #SGMO #MDCO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 805

Issue No. 805 (dated 6/11/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH, #CBMG, #IMGN, #INCY, #ISIS, #MDCO, #NKTR, #OGXI, #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

H2 OUTLOOK CNDO, OGXI, SGMO

H2 OUTLOOK CNDO, OGXI, SGMO: MTSL Stock of the Year Recommendation Coronado BioSciences has pulled back from an intraday high of $12.70 (on 4/23) to $7.55. The stock is still up 67% YTD, however the pullback from the high is no doubt a meaningful one…

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by